St. Joseph Cancer Center - Clinical Trials: Lymphoma
 

Non-Hodgkin’s Lymphoma, Follicular:

  • SWOG 0801: A Phase II Study of lodine-131 Labeled advanced, Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients with Advanced Stage Follicular Non-Hodgkin’s Lymphoma

Non-Hodgkin’s Lymphoma, Large B-Cell:

  • SWOG 0433: A Phase II Study of Iodine-131-Labeled Monoclonal Anti-B1 Antibody (I-131 Tositumomab) in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Diffuse Large B-Cell NHL
     

  • CTSU C50303: A Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

Non-Hodgkin’s Lymphoma, Mantle Cell:

  • None currently

Non-Hodgkin’s Lymphoma,T-Cell:

  • SWOG 0350: Phase II Trial of Cisplatin Plus Etoposide Plus Gemcitabine Plus Solumedrol (PEGS) in Peripheral T-Cell Non-Hodgkin’s Lymphoma

Hodgkin’s Lymphoma, Recurrent or Primary Refractory:

  • SWOG 0816: A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging

Relapsed or Refractory Lymphoid Malignancies:

  • PSOC 2302: A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies

B-Cell Chronic Lymphocytic Leukemia or SLL:

  • None currently

Lymphoma, Ancillary Study:

  • SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol
     

  • SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease, Ancillary

For more information on the above clinical trials: Cheryl Patz, RN, OCN, CCRC, 360.715.4133

 

Return to previous page

Cancer Services

Cancer Committee

Cancer Program